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It has been previously demonstrated that brain-
derived neurotrophic factor (BDNF) regulates glu-
cose metabolism and energy expenditure in rodent
diabetic models such as C57BL/KsJ-leprdb/leprab
(db/db) mice. Central administration of BDNF has
been found to reduce blood glucose in db/db mice,
suggesting that BDNF acts through the central nerv-
ous system. In the present study we have expanded
these investigations to explore the effect of central
administration of BDNF on energy metabolism. In-
tracerebroventricular administration of BDNF low-
ered blood glucose and increased pancreatic insulin
content of db/db mice compared with vehicle-treated
pellet pair-fed db/db mice. While body temperatures
of the pellet pair-fed db/db mice given vehicle were
reduced because of restricted food supply in this
pair-feeding condition, BDNF treatment remarkably
alleviated the reduction of body temperature sug-
gesting the enhancement of thermogenesis. BDNF
enhanced norepinephrine turnover and increased
uncoupling protein-1 mRNA expression in the inter-
scapular brown adipose tissue. Our evidence indi-
cates that BDNF activates the sympathetic nervous
system via the central nervous system and regulates
energy expenditure in obese diabetic animals.
Keywords: Neurotrophic factor; Intracerebroventricular ad-
ministration; Energy expenditure; Glucose metabolism;
Norepinephrine turnover
Abbreviations: BDNF, brain-derived neurotrophic factor; NE,
norepinephrine; UCP-1, uncoupling protein-i; BAT, brown
adipose tissue
INTRODUCTION
Brain-derived neurotrophic factor (BDNF), a
member of the neurotrophin family, has been
widely demonstrated to function in the central
and peripheral nervous systems and motor neu-
rons in the fetus and in adulthood. [1,2,3,4,5,6]
BDNF is known to regulate neural development
and regeneration, promote neurite extension
and maintain neuronal survival. [7,8’9’1’11] In addi-
tion to those diverse roles of BDNF in the nerv-
ous system, we have discovered that BDNF
plays important roles in the endocrine system
and regulates glucose metabolism. I121
We have shown that systemic administration of
BDNF improves glucose metabolism in obese dia-
betic C57BL/KsJ-lepreb/lepreb (db/db) mice. [12’13]
Although BDNF also suppresses food intake in
such hyperphagic obese mice, we developed a
novel apparatus to pair-feed vehicle-treated con-
trol mice precisely to BDNF-treated mice and
demonstrated that BDNF has a major hypo-
glycemic effect independent of appetite.I41 We
have clarified the unique profile of peripheral
BDNF administration in regulating glucose me-
tabolism: (1) BDNF enhances insulin sensitivity
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and ameliorates insulin resistance; (2) the hypo-
glycemic effect of BDNF lasts long after the
cessation of treatment; and (3) insulin content in
pancreas is increased and in histological observa-
tions, insulin-positive pancreatic beta cells are
regranulated by BDNF administration.I13,14,151 In-
terestingly, in addition to its efficacy on glucose
metabolism, BDNF also prevents the reduction of
body temperature in the db/db mice deprived of
food supply. [141 This finding indicates that BDNF
ameliorates the impaired energy balance in dia-
betic mice. However, the mechanism by which
BDNF regulates glucose metabolism and energy
expenditure still remains unclear. We have not yet
obtained any evidence to show the direct effects
of BDNF on glucose metabolism in cultured cells
from peripheral tissues such as liver, muscle, and
adipose tissue. Under the precise control of food
intake by means of our pellet pair-fed.apparatus,
we have demonstrated that intracerebroventricu-
lar administration of BDNF shows the similar
anorectic and hypoglycemic effects as seen in
peripheral administration in db/db mice. [141 We
thus hypothesize that BDNF regulates glucose
metabolism by acting through the central nervous
system. To evaluate this hypothesis we have ana-
lyzed the effects of intracerebroventricular BDNF
administration on energy expenditure in the
present study. We explore the action of BDNF
in regulating thermogenesis and demonstrate
the involvement of the sympathetic nervous sys-
tem in this process.
were performed basically as described in our pre-
vious study. I141 The supply of pellets to the BDNF-
treated mice was not limited, but the supply of
pellets to the vehicle-treated mice was limited to
the number of those consumed by the BDNF-
treated mice. All animal experiments were done
according to the guidelines of the Sumitomo Phar-
maceuticals Committee on Animal Research.
Intracerebroventricular Administration
of BDNF
Human recombinant BDNF (N-terminal methion-
ine-free, Regeneron Pharmaceuticals, Tarrytown,
NY) was administered using artificial cerebro-
spinal fluid (aCSF; 0.166g/L CaCI2, 7.014g/L
NaC1, 0.298g/L KC1, 0.203g/L MgCla/6H20
and 2.10g/L NaHCO3) as a vehicle for in-
tracerebroventricular administration. Mice were
anesthetized with diethyl ether, and fifteen
micrograms of BDNF (3txl/mouse) were injected
through a Hamilton syringe into the lateral cere-
bral ventricle according to the following coordi-
nates: 1.0mm lateral to the bregma and 3.0mm
ventral to the skull surface. For the pellet-pair feed
experiment, mice received a total of five injections,
alternating sides of the head for each injection,
with the injections being given every other day
(three on one side of the head and two on the
other side). Both sides of injection placement were
verified by injecting Evans Blue in the same man-
ner at the end of the experiment.
MATERIALS AND METHODS
Animals
Male C57BL/KsJ-db/db mice were obtained from
Clea Japan Inc. (Tokyo, Japan). Mice were singly
housed and the treatments started at 10-12 weeks
of age. Animals were given food (CE-2, Clea Japan
Inc.) and water ad libitum except for the pair-feed-
ing experiment. Pellet pair-fed mice were housed
in the synchronized pellet pair-feeding apparatus
(Sumitomo Pharmaceuticals and Osaka Micro
Systems, Osaka, Japan). Pair-feeding experiments
Measurement of Blood Glucose
and Insulin
Blood samples were collected from tail vein, and
blood glucose was measured by the GLUCOSE
CII-TEST WAKO (Mutarotase-glucose oxidase
method, Wako Chemical, Osaka, Japan). Plasma
insulin concentrations were measured by ELISA
(Levis-insulin-mouse; Shibayagi, Gunma, Japan).
At the end of the treatment, the whole pancreas
was resected from each mouse and divided
into splenic and duodenal regions. Splenic re-
gions were weighed, minced, and homogenized
in acid-ethanol solution (75% ethanol, 23.5%
INTERNATIONAL JOURNAL OF EXPERIMENTAL DIABETES RESEARCHBDNF CENTRALLY REGULATES ENERGY EXPENDITURE 203
distilled water, 1.5% conc. HC1). After overnight
incubation at 4C the suspensions were cen-
trifuged, and the supernatants were collected
and assayed for insulin content.
Body Temperature and Thermographic
Imaging Analysis
Body temperature was measured using an elec-
tron thermistor (Model BAT-12, Physitemp,
Clifton, NJ) equipped with rectal probe (RET-
3, Physitemp, Clifton, NJ). Skin temperature
was imaged by thermography (TVS-8000MkII,




The effect of BDNF on norepinephrine turnover
was assessed using a slightly modified version of
the method previously reported by Collins. [16]
db/db mice received intracerebroventricular ad-
ministration of either BDNF (15 txg/mouse) or ve-
hicle at the beginning of a dark cycle, and then
food was removed. Two hours after BDNF or vehi-
cle treatment, c-methyl-p-tyrosine methyl ester
(250mg/kg, Sigma, St. Louise, MO), an inhibitor
of tyrosine hydroxylase, was intraperitoneally
injected to block de novo catecholamine synthesis.
The mice were decapitated two hours after c-MT
injection and the interscapular brown adipose
tissue (BAT) was immediately dissected, weighed
and then frozen in liquid nitrogen. The BAT was
homogenized with 0.1N perchloric acid containing
5mM EDTA. Homogenates were filtrated through
a 0.22xm mesh membrane to remove debris. Nore-
pinephrine content in homogenates was measured
using an HPLC system (LC-10A, Shimadzu Instru-
mentation, Kyoto, Japan) equipped with a column
(CA-5DS, Eicom, Kyoto, Japan).
Northern Blot Analysis
db/db mice were intracerebroventricularly injected
with either BDNF or vehicle at the beginning of a
dark cycle and then food was removed. Animals
were sacrificed 4 hours after BDNF (15 Ixg/mouse)
or vehicle treatment; interscapular BAT was ex-
cised and frozen immediately. RNA was prepared
from the tissues with Trizol (Gibco BRL Life Tech-
nologies, Rockville, MD, USA) using the manufac-
turer’s protocol. Yield and purity of RNA were
determined by spectrophotometric absorption
analysis at 260/280nm. 3g of total RNA was
electrophoresed in a 1% agarose gel containing
formaldehyde and then transferred to GT probe
membranes (Bio-Rad Laboratories, Hercules, CA,
USA). A 1071-base pair rat uncoupling protein-1
(UCP1) probe (nucleotides 84-1154 in Genebank
accession no. Ml1814) was obtained by reverse
transcriptase-polymerase chain reaction (RT-PCR)
from rat BAT RNA using primers 5’-CCA CAG
GAATTC GAAGTT GAG AGT TCG GTA and 5’-
CCC AGC TCT AGA GCC CAG CAT AGG AGC
CCA as reported previously.[71 A 349-base pair
mouse ]3-actin probe (nucleotides 728-1076 in
Genebank accession no. M12481) was obtained by
RT-PCR from mouse liver RNA using primers 5’-
TGG AAT CCT GTG GCA TCC ATG AAA C
and 5’-TAAAAC GCA GCT CAG TAACAG TCC
G. All probes were verified by sequencing. Probes
were randomly labeled using a BcaBest labeling
kit (Takara, Ohtsu, Japan) with [c-32p]-deoxy
CTP (Amersham Pharmacia Biotech, Bucking-
hamshire, England). Hybridization was carried
out at 65C in 0.25M sodium phosphate (pH
7.2)/7% SDS, and blots were washed twice with
20mM sodium phosphate (pH 7.2)/5% SDS
and then with 20mM sodium phosphate (pH
7.2)/1% SDS. Hybridization signals were quanti-
fied using a bio-imaging analyzer BAS2000 (Fuji
Photo Film, Tokyo, Japan).
Statistical Analysis
All data are presented as means + SD. The statis-
tical calculations were performed using SAS
software (SAS Institute, Cary, NC), and differ-
ences between individual groups were analyzed
by the Student’s t-test, the Dunnett’s test or
Jonckheere-Terpstra test. P< 0.05 was considered
statistically significant.
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RESULTS
Effect of Intracerebroventricular
Administration of BDNF on Glucose
Metabolism
15tg BDNF per mouse or the same volume (31/
mouse) of vehicle solution was administered in-
tracerebroventricularly to db/db mice every other
day 5 times. After intracerebroventricular BDNF
administration, the food intake of db/db mice de-
creased as shown in Figure 1A. Food intake of
the vehicle-treated pellet pair-fed db/db mice was
very well synchronized to the BDNF-treated
mice. Compared with such vehicle-treated con-
trol mice, the repetitive intracerebroventricular
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FIGURE Effects of intracerebroventricular BDNF adminis-
tration on food intake (A), blood glucose concentration (B) and
body weight (C) in db/db mice. BDNF (151g/mouse) or vehi-
cle was administered on alternate days to db/db mice housed
in the pellet pair-feeding apparatus. Data are presented as
mean +_SD (n =9). **P< 0.01 vs. vehicle by Student’s t-test.
administration of BDNF significantly lowered
blood glucose concentrations in db/db mice (Fig.
1B). There was no significant difference in body
weight between BDNF-treated and the pellet pair-
fed mice (Fig. 1C). To study the dose-dependency
of repetitive intracerebroventricular administra-
tion, three different doses (0.15, 1.5 and
15g/mouse) of BDNF were injected every other
day to db/db mice, respectively. BDNF was found
to be dose-dependently effective in lowering
blood glucose concentration and reducing food in-
take of db/db mice by Jonckheere-Terpstra test
(blood glucose; P =0.002, food intake; P 0.009).
15 ig/mouse of BDNF significantly reduced food
intake and lowered blood glucose concentration
(Figs. 2A, B).
In addition to blood glucose, we next analyzed
the effect of intracerebroventricular administra-
tion of BDNF on plasma insulin levels. As shown
in Table I, plasma insulin concentrations of both
A
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FIGURE 2 Dose-response effects of intracerebroventricular
BDNF administration on food intake (A) and blood glucose
concentration (B) in db/db mice. BDNF (0.15, 1.5, 15bg/mouse)
or vehicle was administered on alternate days to ad libitum-fed
db/db mice. Data are presented as mean SD (n 7 or 8). *P <
0.05, **P 0.01 vs. vehicle by Dunnett’s test. BDNF was found
to be dose-dependently effective in lowering blood glucose
concentration and reducing food intake of db/db mice by
Jonckheere-Terpstra test (blood glucose; P=0.002, food
intake; P 0.009).
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TABLE Effect of intracerebroventricular BDNF adminis-
tration on plasma insulin concentration and pancreatic in-
sulin content in db/db mice. BDNF (15g/shot) or vehicle
was administered on alternate days for a total of five injec-
tions to db/db mice housed in the pellet pair-feeding appa-
ratus. Plasma insulin concentration was measured at Days 0
(baseline) and 10. Pancreases were removed from the mice at
Day 10 and the pancreatic insulin content was measured.











Pair-feed + vehicle N.A.
BDNF N.A.
P < 0.01 vs. vehicle by Student’s t-test.
92.9 47.3
606.8 161.4"*
the BDNF-treated db/db mice and pellet pair-fed
db/db mice decreased during the experimental pe-
riod. However, the plasma insulin concentration
of BDNF-treated db/db mice tended to be lower
than that of the pellet pair-fed mice after repetitive
intracerebroventricular administrations. Since we
have previously found that subcutaneous admin-
istration of BDNF increases pancreatic insulin con-
tents of db/db mice, we then analyzed pancreatic
insulin content after repetitive intracerebroventri-
cular administration of BDNE The pancreatic in-
sulin content of BDNF-treated mice was found to
be approximately 6-fold higher than that of the
pellet pair-fed mice (Tab. I). These findings sug-
gest that intracerebroventricular administration
as well as subcutaneous administration of BDNF
regulates glucose metabolism in a similar fashion.
Effect of Intracerebroventricular
Administration of BDNF on Body
Temperature
To verify our hypothesis that BDNF regulates glu-
cose metabolism by acting through the brain, we
analyzed the effect of intracerebroventricular
BDNF administration on the rectal temperature
of db/db mice in this study. Compared with ad
libitum-fed db/db mice (approximately 37-38C),
the rectal temperature of the vehicle-treated pellet
pair-fed db/db mice was lower, probably due to the
reduced food intake that was synchronized with
BDNF-treated mice (Tab. II). The rectal tempera-
ture of the BDNF-treated db/db mice at Days i and
10 was significantly higher than the vehicle-
treated pellet pair-fed db/db mice and almost com-
parable to ad libitum-fed mice in spite of a reduced
food intake that was approximately the same as
the pair-fed mice. We then examined the skin’ tem-
perature of these db/db mice by thermography
imaging analysis (Fig. 3). Whereas the skin tem-
perature of a typical vehicle-treated pellet pair-fed
mouse was lower than an ad libitum-fed mouse,
the skin temperature of the paired BDNF-treated
mouse recovered. A relatively higher temperature
was observed in the interscapular region of the
BDNF-treated mouse suggesting enhancement of
thermogenesis in the brown adipose tissue (BAT).
TABLE II Rectal temperature of db/db mice with intracere-
broventricular BDNF administration. BDNF (15g/shot) or
vehicle was administered on alternate days for a total of five
injections to db/db mice housed in the pellet pair-feeding appa-
ratus. Rectal temperatures were measured at the next day af-
ter the first injection (Day 1) and two days after the last (fifth)
injection (Day 10). Data are presented as mean SD (n=9)
Day 10
Rectal temperature (C)
Pair-feed + vehicle 34.6 1.8 35.0 _+ 1.1
BDNF 37.0 0.4** 37.2 +_ 1.2"*
P < 0.01 vs. vehicle by Student’s t-test.
36.0
2g.O
FIGURE 3 Thermographic imaging analysis of the back
skin temperature of db/db mice after intracerebroventricular
BDNF administration. Thermographic imaging analysis of a
BDNF (15g/mouse, on alternate days)-treated mouse (a),
a vehicle-treated mouse pair-fed to the BDNF-treated mouse
(b), and a vehicle-treated mouse fed ad libitum (c). Analysis
was performed at Day 10.
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Enhancement of Norepinephrine
Turnover in db/db Mice Treated
with BDNF
In order to explore the effect of BDNF on sympa-
thetic nerve activity, we examined NE utilization
(i.e., NE turnover) in BAT of a BDNF-treated db/db
mouse. To assess NE turnover, NE contents in
BAT were measured after blocking catecholamine
synthesis with administration of a-methyl-p-tyro-
sine (a-MT), a tyrosine hydroxylase inhibitor. Two
hours prior to c’MT administration, db/db mice
received a single intracerebroventricular adminis-
tration of either BDNF or vehicle. After adminis-
tration of a-MT there was a decrease in the NE
contents of the BAT in db/db mice that received ve-
hicle intracerebroventricularly, indicating a block-
age of catecholamine synthesis. Compared with
such control animals, intracerebroventricular ad-
ministration of BDNF elicited a larger reduction in
NE contents in interscapular BAT, indicating en-
hancement ofNE turnover (Fig. 4).
Effects of a Single Intracerebroventricular
Administration of BDNF on mRNA
Expression of Uncoupling Protein-1
To study the action mechanism by which BDNF
enhances energy expenditure in greater detail we
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FIGURE 4 NE turnover in db/db mice treated with BDNF.
Following a single intracerebroventricular administration of
BDNF (15g/mouse), the tyrosine hydroxylase inhibitor a-
methyl-p-tyrosine (a-MT) was intraperitoneally injected. NE
contents were measured 2hr after injecting the blocking
reagent. NE turnover was determined from the decrease in
NE content after blockage of catecholamine biosynthesis.
Data are presented as mean +SD (n =6 or 8). *P <0.05 vs.









FIGURE 5 Effects of a single intracerebro,entricular ad-
ministration of BDNF on mRNA expression of uncoupling
protein-1 in brown adipose tissue.
BDNF (15g/mouse) or vehicle was administered intra-
cerebroventricularly to db/db mice and then fasting was
started. Four hours after BDNF or vehicle administration, the
interscapular brown adipose tissue was dissected and total
RNA was isolated. Northern blot analysis (UCP1 and fi-actin
probes) of the total RNA (3g) was then performed. Data
are shown as means SD (n 4). *P <0.05 vs. vehicle by
Student’s t-test. The left panels show representative blots.
administration of BDNF on the expression of un-
coupling protein (UCP)-I gene in BAT. db/db
mice were intracerebroventricularly adminis-
trated with either BDNF (15g/mouse) or vehi-
cle followed by food removal. Four hours after
BDNF or vehicle administration, total RNA was
prepared from BAT and subjected to Northern
blot analysis using UCP-1 cDNA as a probe. As
shown in Figure 5, a single intracerebroventricu-
lar administration of BDNF increased UCP-1
mRNA in BAT by 1.5-fold.
DISCUSSION
We have previously shown that peripheral subcu-
taneous administration of BDNF lowered food in-
take and blood glucose concentration of diabetic
db/db mice with accompanying obesity and hyper-
insulinemia. [12’131 We have also demonstrated
the hypoglycemic effect of BDNF on db/db mice
even under strict pellet pair-feeding conditions
using our novel apparatus[141 which indicates that
blood glucose is actually being lowered by BDNF
apart from the hypoglycemic effect ascribed to
hypophagia. Since BDNF does not lower blood
glucose levels of normal rodents and streptozo-
tocin-treated rodent models, it is unlikely that
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BDNF enhances insulin secretion from the pan-
creas. [12,141 In streptozotocin-treated mice, we
have found concomitant administration of BDNF
with insulin enhances the acute hypoglycemic ef-
fect of insulin. I141 These data suggest that pe-
ripheral subcutaneous administration of BDNF
enhances insulin sensitivity or ameliorates insulin
resistance or both in peripheral tissues.
In our studies so far with cultured adipocyte
and myotubule cell lines we have observed no
direct action of BDNF on insulin stimulated
2-deoxyglucose uptake (unpublished data), al-
though peripheral tissues such as adipose tissue
and muscle are involved in insulin-dependent
glucose metabolism. Moreover, it was reported
elsewhere that intracerebroventricular infusion of
BDNF suppresses food intake and body weight
gain but does not affect blood glucose level in
normoglycemic (Long-Evans) rats. [181 Therefore,
we investigated the effect of central administra-
tion of BDNF on glucose metabolism in hyper-
glycemic animals. Our present study clearly
demonstrated that central BDNF administration
reduces blood glucose and also increases pancre-
atic insulin contents in obese hyperglycemic db/db
mice under strict pellet pair-feeding conditions.
In comparison with subcutaneous administration,
a much lower dose (approximately 1/100) of
BDNF was found to be effective with central ad-
ministration. These results indicate that BDNF
regulates glucose metabolism and maybe pancre-
atic function through the central nervous system.
Previously, we have found that subcutaneous
administration of BDNF raised rectal and skin
temperatures in db/db mice,[141 indicating the regu-
latory role of BDNF on energy metabolism. In
the present study we were also able to repro-
duce these effects of BDNF through central ad-
ministration. It is well known that the sympathetic
nervous system is involved in regulating thermo-
genesis and maintaining body temperature in
mammals. I191 In this study, we demonstrated that
central administration of BDNF rapidly enhances
NE turnover in thermogenic brown adipose tissue
(BAT) of db/db mice. This is consistent with the
present thermographic data in which skin tem-
perature increased in the interscapular region that
abundantly contains BAT. BAT is a major source
of non-shivering thermogenesis in rodents[21 and
the thermogenic ability of BAT is thought to be
due to UCP-1.[2] Intracerebroventricular adminis-
tration of BDNF also rapidly increased UCP-1
mRNA expression in BAT of db/db mice demon-
strating the central regulation of BDNF in energy
expenditure. Taken together, the above indicates
that BDNF regulates energy metabolism through
the central nervous system and the auton’omic
nervous system.
It is well known that the blood brain barrier
restricts the transport of peptides and proteins
between the blood and the brain. [221 It has been
reported however that BDNF passes through the
blood brain barrier by a saturable transport sys-
tem and quickly enters into brain. [23,24] In our
preliminary experiments, subcutaneous treat-
ment of BDNF as well as intracerebroventricular
treatment rapidly showed anorexic effect in
db/db mice (data not shown). Since subcutaneous
administration of BDNF ameliorated the energy
expenditure in our previous study, [14] BDNF ad-
ministered even peripherally may rapidly enter
the brain and regulate energy metabolism in
obese diabetic animals.
The pharmacological profiles of BDNF shown
in this study reminded us of leptin, an adipocyte-
derived satiety hormone regulating body adi-
posity by modulating food intake and energy
metabolism.[8,25,26] Peripheral administration of
leptin stimulates sympathetic nerve activity in in-
terscapular BAT and norepinephrine turnover[6,27]
and regulates the expression of UCP1 by modulat-
ing the sympathetic nervous system.[28,29] Since
the functional form of the leptin receptor (Ob-Rb)
is expressed in the hypothalamus, a major site of
metabolic regulation by the autonomic nervous
system,I31 intracerebroventricular or intrahypo-
thalamic administration of leptin can reproduce
most of the effects of peripheral leptin administra-
tion. [26’31’32] Leptin administered peripherally may
access the hypothalamus via receptor-mediated
transport, and regulate energy expenditure and
food intake primarily by interacting with Ob-Rb
in the hypothalamus. Therefore, many of the thera-
peutic profiles of leptin are very similar to BDNE
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Since the functional full-length form of BDNF re-
ceptor, trkB is expressed in the hypothalamus,[33,34]
it is plausible that BDNF may act via the hypo-
thalamic neuronal system. More studies will be
needed to clarify the action mechanisms of BDNF
in comparison with leptin.
In conclusion, the present study has demon-
strated that central administration of BDNF
regulates the glucose metabolism and energy
expenditure of obese diabetic animals in a simi-
lar fashion to peripheral administration. These
results further suggest that BDNF modulates
sympathetic nerve activity through central regu-
lation in the hypothalamus and affects energy
expenditure.
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